Substantial evidence shows that inflammation promotes oncogenesis and, occasionally,
participates in cancer rejection. This paradox can be accounted for by a dynamic switch from …

Toll-like receptor (TLR) agonists are being developed for use as vaccine adjuvants and as
stand-alone immunomodulators because of their ability to stimulate innate and adaptive …

Toll-like receptor (TLR) agonists as the potent stimulants of an innate immune system hold
promises for applications in anticancer immunotherapy. However, most of them are limited in …

In order to create novel compounds which possess potent interferon (IFN) inducing activities
with excellent oral bioavailabilities, a series of 8-hydroxyadenines, which have various …

Background Imiquimod, a potent immunomodulator, not having a direct antiproliferative
activity, was found to be effective in genital and cutaneous premalignancies and …

Abstract Background Imiquimod is a Toll-like receptor-7 agonist capable of inducing
complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies. We …

Induction of IFNα in the upper airways via activation of TLR7 represents a novel
immunomodulatory approach to the treatment of allergic asthma. Exploration of 8 …

Imidazoquinolines represented by imiquimod and its derivative S-27609, have previously
been shown to have potent antiviral and antitumor activity in several mammalian models …

Aim To describe the ophthalmic side-effects of topical imiquimod for periocular actinic
keratoses, squamous cell carcinoma in situ and basal cell carcinoma. Method A …

Structural modification of imiquimod (1), which is known as an interferon-α (IFN-α) inducer,
for the aim of finding a novel and small-molecule tumor necrosis factor-α (TNF-α) suppressor …